electroCore, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
electroCore reported Q3 2026 net sales of $9.7M (up 12% from $8.7M in Q3 2025), with GAAP net loss improving 61% to $1.3M and Adjusted EBITDA loss improving 67% to $0.7M. VA prescription revenue grew 25% in Q3; Quell product sales reached $1.2M (up 102%). Company revised FY2026 guidance to $39–42M revenue and introduced preliminary FY2027 guidance of 30–40% growth, targeting first positive Adjusted EBITDA quarter by end of 2027. Cash position declined from $11.6M (Dec 2025) to $7.5M (Sep 2026); company carries stockholders' deficit of $2.5M.
Why this rating
Revenue growth and operating loss shrinkage are real operational progress; however, cash burn ($4.1M in 9 months), persistent GAAP losses, and negative equity make runway and execution risk material for a $28M market-cap company. Guidance reversion and FDA 510(k) uncertainty add risk.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.